Understanding Best Care Practices for Hemorrhagic Stroke: A Focus on the Role of DOAC Reversals

CME: 1.0

Target Audience

This educational activity is directed toward neurointensivists, critical care clinicians, and neurologists. Cardiologists, nurse practitioners, physician assistant, nurses, primary care physicians, and other health care professionals involved in the treatment of patients experiencing bleeding episodes are invited to participate.

Program Overview

Increased risk of bleeding is a known complication of anticoagulation therapies, including direct oral anticoagulants (DOACs). Although DOACs demonstrated favorable safety and efficacy profiles in the absence of a specific reversal agent, situations such as overdose, serious bleeding, or the need for immediate surgery warranted a call to action to develop DOAC reversal agents. This call to action was answered, and there are now 2 FDA-approved DOAC reversal agents. Ongoing education about DOAC reversal is vital for clinicians involved in critical care. In this educational program, experts discuss the agents and best practices for the use of DOAC reversal in patients with intracranial hemorrhage.

This educational activity is an archive of the live virtual symposium held on October 27, 2021.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss intracerebral hemogghage (ICH) risk and assessment in patients on DOAC therapy
  • Evaluate the safety and efficacy of DOAC reversal agents
  • Review therapeutic management of ICH based on clinical indications and safety and efficacy data of DOAC reversal agents
  • Apply current practice guidelines on DOAC reversal therapies for optimal management of ICH and hemorrhagic stroke

Post a comment to this article